Ryan W. Stidham, MD, MSc
Articles
December 6th 2018
Adalimumab Persistence for Inflammatory Bowel Disease in Veteran and Insured Cohorts
Shail M. Govani, MD, MSc Rachel Lipson, MSc Mohamed Noureldin, MBBS, MSc Wyndy Wiitala, PhD Peter D.R. Higgins, MD, PhD, MSc Sameer D. Saini, MD, MSc Jacqueline A. Pugh, MD Dawn I. Velligan, PhD Ryan W. Stidham, MD, MSc Akbar K. Waljee, MD, MSc
Veterans with inflammatory bowel disease taking adalimumab appear to be more likely to remain on the drug 1 year after initiation than patients who are privately insured.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
